D.E. Shaw & Co
ORMP icon

D.E. Shaw & Co’s Oramed Pharmaceuticals ORMP Stock Holding History

D.E. Shaw & Co’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,566
Closed -$99.1K – 4780
2024
Q2 		$99.1K Sell
38,566
-31,936
-45% -$75.9K ﹤0.01% 4164
2024
Q1 		$206K Buy
70,502
+11,432
+19% +$32K ﹤0.01% 3910
2023
Q4 		$136K Buy
+59,070
New +$126K ﹤0.01% 3934
2022
Q2 		– Sell
-13,744
Closed -$119K – 5649
2022
Q1 		$119K Sell
13,744
-161,051
-92% -$1.65M ﹤0.01% 4973
2021
Q4 		$2.5M Buy
+174,795
New +$3.65M ﹤0.01% 3146
2015
Q1 		– Sell
-27,708
Closed -$126K – 3896
2014
Q4 		$126K Buy
27,708
+10,705
+63% +$70.4K ﹤0.01% 3879
2014
Q3 		$137K Sell
17,003
-5,041
-23% -$44.8K ﹤0.01% 3950
2014
Q2 		$212K Buy
+22,044
New +$225K ﹤0.01% 3965

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

D.E. Shaw & Co's ORMP Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 38,566 shares — an estimated $99.1K sold.

D.E. Shaw & Co first reported a position in ORMP in Q2 2014 and held it in 8 quarters. The position peaked at $2.5M in Q4 2021. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 38,566 Oramed Pharmaceuticals shares in Q3 2024, an estimated $99.1K.
  • D.E. Shaw & Co first reported a position in Oramed Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • D.E. Shaw & Co's Oramed Pharmaceuticals position peaked at $2.5M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.